These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 24587179)
21. Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer. Verma S; Shankar E; Chan ER; Gupta S Cells; 2020 Nov; 9(12):. PubMed ID: 33255236 [TBL] [Abstract][Full Text] [Related]
22. Cellular interactions in the tropism of prostate cancer to bone. Sikes RA; Nicholson BE; Koeneman KS; Edlund NM; Bissonette EA; Bradley MJ; Thalmann GN; Cecchini MG; Pienta KJ; Chung LW Int J Cancer; 2004 Jul; 110(4):497-503. PubMed ID: 15122581 [TBL] [Abstract][Full Text] [Related]
23. Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells. Babcook MA; Sramkoski RM; Fujioka H; Daneshgari F; Almasan A; Shukla S; Nanavaty RR; Gupta S Cell Death Dis; 2014 Nov; 5(11):e1536. PubMed ID: 25412314 [TBL] [Abstract][Full Text] [Related]
24. Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration. Jia L; Gui B; Zheng D; Decker KF; Tinay I; Tan M; Wang X; Kibel AS Prostate; 2017 Jun; 77(9):1000-1011. PubMed ID: 28422308 [TBL] [Abstract][Full Text] [Related]
25. [Type IV collagenase expression in human prostate carcinoma cell lines with different metastasis potentials]. Zhang LL; He DL; Li X; Li L; Zhu GD; Wang XY Zhonghua Nan Ke Xue; 2006 Oct; 12(10):913-6. PubMed ID: 17121023 [TBL] [Abstract][Full Text] [Related]
26. Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone. Jin R; Sterling JA; Edwards JR; DeGraff DJ; Lee C; Park SI; Matusik RJ PLoS One; 2013; 8(4):e60983. PubMed ID: 23577181 [TBL] [Abstract][Full Text] [Related]
27. Expression profiles of androgen independent bone metastatic prostate cancer cells indicate up-regulation of the putative serine-threonine kinase GS3955. Bisoffi M; Klima I; Gresko E; Durfee PN; Hines WC; Griffith JK; Studer UE; Thalmann GN J Urol; 2004 Sep; 172(3):1145-50. PubMed ID: 15311059 [TBL] [Abstract][Full Text] [Related]
28. Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer. Jin Y; Cui Z; Li X; Jin X; Peng J Oncotarget; 2017 Apr; 8(16):26090-26099. PubMed ID: 28212533 [TBL] [Abstract][Full Text] [Related]
29. [Comparative analysis of gene expression in normal and cancer human prostate cell lines]. Rosenberg IeE; Herashchenko HV; Kashuba VI Ukr Biochem J; 2014; 86(2):119-28. PubMed ID: 24868918 [TBL] [Abstract][Full Text] [Related]
30. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. Saraon P; Cretu D; Musrap N; Karagiannis GS; Batruch I; Drabovich AP; van der Kwast T; Mizokami A; Morrissey C; Jarvi K; Diamandis EP Mol Cell Proteomics; 2013 Jun; 12(6):1589-601. PubMed ID: 23443136 [TBL] [Abstract][Full Text] [Related]
31. Application of Affymetrix array and Massively Parallel Signature Sequencing for identification of genes involved in prostate cancer progression. Oudes AJ; Roach JC; Walashek LS; Eichner LJ; True LD; Vessella RL; Liu AY BMC Cancer; 2005 Jul; 5():86. PubMed ID: 16042785 [TBL] [Abstract][Full Text] [Related]
32. MiR-543 Promotes Proliferation and Epithelial-Mesenchymal Transition in Prostate Cancer via Targeting RKIP. Du Y; Liu XH; Zhu HC; Wang L; Ning JZ; Xiao CC Cell Physiol Biochem; 2017; 41(3):1135-1146. PubMed ID: 28245474 [TBL] [Abstract][Full Text] [Related]
33. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Dorai T; Dutcher JP; Dempster DW; Wiernik PH Prostate; 2004 Jun; 60(1):1-17. PubMed ID: 15129424 [TBL] [Abstract][Full Text] [Related]
34. Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines. Seiler D; Zheng J; Liu G; Wang S; Yamashiro J; Reiter RE; Huang J; Zeng G Prostate; 2013 Sep; 73(13):1378-90. PubMed ID: 23728788 [TBL] [Abstract][Full Text] [Related]
35. COX-2 specific inhibitor, NS-398, increases macrophage migration inhibitory factor expression and induces neuroendocrine differentiation in C4-2b prostate cancer cells. Meyer-Siegler K Mol Med; 2001 Dec; 7(12):850-60. PubMed ID: 11876163 [TBL] [Abstract][Full Text] [Related]
36. EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling. DeHaan AM; Wolters NM; Keller ET; Ignatoski KM Prostate; 2009 Apr; 69(5):528-37. PubMed ID: 19143022 [TBL] [Abstract][Full Text] [Related]
37. MK591, a second generation leukotriene biosynthesis inhibitor, prevents invasion and induces apoptosis in the bone-invading C4-2B human prostate cancer cells: implications for the treatment of castration-resistant, bone-metastatic prostate cancer. Sarveswaran S; Ghosh R; Morisetty S; Ghosh J PLoS One; 2015; 10(4):e0122805. PubMed ID: 25875826 [TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239 [TBL] [Abstract][Full Text] [Related]